Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Intangibles (2019 - 2025)

Vivos Therapeutics has reported Intangibles over the past 7 years, most recently at $4.0 million for Q4 2025.

  • Quarterly Intangibles rose 889.0% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 889.0% year-over-year, with the annual reading at $4.0 million for FY2025, 889.0% up from the prior year.
  • Intangibles was $4.0 million for Q4 2025 at Vivos Therapeutics, up from $2.2 million in the prior quarter.
  • Over five years, Intangibles peaked at $4.0 million in Q4 2025 and troughed at $301690.0 in Q1 2021.
  • The 5-year median for Intangibles is $401500.0 (2024), against an average of $741189.4.
  • Year-over-year, Intangibles decreased 21.94% in 2022 and then soared 889.0% in 2025.
  • A 5-year view of Intangibles shows it stood at $341000.0 in 2021, then decreased by 11.44% to $302000.0 in 2022, then soared by 39.07% to $420000.0 in 2023, then dropped by 2.62% to $409000.0 in 2024, then soared by 889.0% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Intangibles are $4.0 million (Q4 2025), $2.2 million (Q3 2025), and $2.2 million (Q2 2025).